Analysis of haematopoietic chimaerism by quantitative real-time polymerase chain reaction

被引:0
作者
L W Harries
C L Wickham
J C Evans
S A Rule
M V Joyner
S Ellard
机构
[1] Royal Devon and Exeter NHS Foundation Trust,Department of Molecular Genetics
[2] Peninsula Medical School,Institute of Biomedical and Clinical Science
[3] Derriford Hospital NHS Healthcare Trust,Department of Haematology
[4] Royal Devon and Exeter NHS Foundation Trust,Department of Haematology
来源
Bone Marrow Transplantation | 2005年 / 35卷
关键词
TaqMan™; chimaerism; SNP; real-time PCR;
D O I
暂无
中图分类号
学科分类号
摘要
Allogeneic bone marrow transplantation (BMT) with marrow ablative conditioning is the treatment of choice for haematopoietic malignancies. The use of nonmyeloablative stem cell transplants has allowed the treatment of patients previously ineligible for BMT because of age or other disease. These reduced conditioning regimes allow the persistence initially of some recipient cells in the blood and bone marrow (haematopoietic chimaerism). Monitoring of the relative proportion of donor and recipient cells is required to assess the success of the procedure, to predict subsequent rejection or impending relapse and to guide the use of donor lymphocyte infusions. We present a quantitative real-time PCR approach for the measurement of haematopoietic chimaerism using the TaqMan™. This approach exploits the presence of single-nucleotide polymorphisms (SNPs) to distinguish cells of patient or donor origin. We have designed and validated a panel of seven allele-specific probes to quantify the contribution of patient and donor cells in the haematopoietic population from 12 patient and donor pairs. We have compared the performance of this approach with an existing method and proved it to be superior in both accuracy and sensitivity. The use of more sensitive and accurate techniques permits earlier intervention for improved clinical outcome.
引用
收藏
页码:283 / 290
页数:7
相关论文
共 95 条
[1]  
Bensinger WI(1996)Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome Blood 88 2787-2793
[2]  
Buckner CD(1979)Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts N Engl J Med 300 1068-1073
[3]  
Anasetti C(1998)Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone Br J Haematol 103 565-567
[4]  
Weiden PL(2000)Mini-allografts: ongoing trials in humans Bone Marrow Transplant 25 345-350
[5]  
Flournoy N(1994)Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia Blood 83 3409-3416
[6]  
Thomas ED(1999)Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse Bone Marrow Transplant 23 475-482
[7]  
Carella AM(2001)Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation Br J Haematol 115 935-944
[8]  
Lerma E(1992)Analysis of late graft failure after allogeneic bone marrow transplantation: detection of residual host cells using amplification of variable number of tandem repeats loci Bone Marrow Transplant 9 107-111
[9]  
Corsetti MT(1997)Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia Bone Marrow Transplant 20 235-241
[10]  
Carella AM(2004)Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme Bone Marrow Transplant 34 1-12